Organization and Business Description Apollo Endosurgery, Inc. is a Delaware corporation with both domestic and foreign wholly-owned subsidiaries. Throughout these Notes "Apollo" and the "Company" refer to Apollo Endosurgery, Inc. and its consolidated subsidiaries. Apollo is a medical technology company primarily focused on the design, development, and commercialization of innovative medical devices. The Company's products are used by gastroenterologists to address a variety of closure needs in the gastrointestinal tract and used by gastroenterologists and bariatric surgeons to treat obesity. The Company's core products include the OverStitch  Endoscopic Suturing System ("ESS") and the Orbera Intragastric Balloon System ("IGB"), which together comprise the Company's Endoscopy products. The Company also offers Orbera Coach, a digital and remotely delivered aftercare program. All devices are regulated by the U.S. Food and Drug Administration (the "FDA") or an equivalent regulatory body outside the U.S. The Company has offices in the United Kingdom, Australia, Italy, and Brazil that oversee commercial activities outside the U.S., and a products manufacturing facility in Costa Rica. All other activities are managed and operated from facilities in Austin, Texas. In December 2018, the Company sold its Lap-Band adjustable gastric banding system ("Surgical") product line to ReShape Lifesciences, Inc ("ReShape") for total cash consideration of $17,000 ("Cash Purchase Price"), of which $10,000 was paid at closing and $2,000 was paid in December 2019. An additional $2,000 and $3,000 is payable on the second and third anniversary of the closing date, respectively. As additional consideration, the Company received substantially all of ReShape's assets exclusively related to ReShape's intragastric balloon product line. Effective December 31, 2018, the Company ceased sales of ReShape's intragastric balloon system. Additionally, the Company entered into a transition services agreement, supply agreement and distribution agreement with ReShape to manufacture Surgical products for ReShape for up to two years, serve as ReShapes distributor of Surgical product outside the U.S. ("OUS") for up to one year and provide other specified services for defined periods of time. As of December 31, 2019, the Company's obligations under the transition and distribution agreements have been completed. Going Concern Uncertainty ASC Topic 205-40, Presentation of Financial Statements - Going Concern (ASC 205-40), requires management to assess the Companys ability to continue as a going concern for one year after the date the financial statements are issued. Under ASC 205-40, management has the responsibility to evaluate whether conditions and/or events raise substantial doubt about the Companys ability to meet future financial obligations as they become due within one year after the date that the financial statements are issued. As required by this standard, managements evaluation shall initially not take into consideration the potential mitigating effects of managements plans that have not been fully implemented as of the date the financial statements are issued. The Company has experienced operating losses since inception and expects its negative cash flows from operating activities to continue and has determined that the Companys existing capital resources are not sufficient to ensure compliance with debt covenant requirements through March 2021. This projection along with the general uncertainty associated with the current COVID-19 pandemic has raised substantial doubt about the Companys ability to continue as a going concern within one year of the issuance date of these Consolidated Financial Statements. The Company will likely require additional funding in order to meet its covenant requirements. In this regard, managements plans include the pursuit of strategic alternatives to finance our business plan, including, but not limited to sales of our common stock, preferred stock, convertible debt securities or debt financings, reduction of planned expenditures, or other sources. There are no assurances that such additional funding will be obtained and that the Company will succeed in its future operations. If the Company cannot successfully raise additional capital and implement its strategic development plan, its liquidity, financial condition and business prospects will be materially and adversely affected.